
Ramya Ramaswami
@ramya_ramaswami
An oncologist caring for people living with HIV #HIVOnc @theNCI|Trained in the ๐ฌ๐ง from many cultures ๐ธ๐ฌ๐ฎ๐ณ now in ๐บ๐ธ |Former @NEJM fellow| Views are mine
ID: 1575844861
07-07-2013 18:57:23
2,2K Tweet
1,1K Followers
1,1K Following




People with HIV are diagnosed with lung cancer 10-15 years earlier than the general population. We need to better understand the risk factors and optimize lung cancer screening for PWH. Our team, led by Randi M. Williams, PhD, MPH, will delve into this topic! Grateful for funding from

๐ข๐๐๐๐ ๐๐๐๐ ๐๐๐๐๐๐๐๐๐๐๐๐! ๐๐ข After nearly 7 years in creation, my new book ๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐: ๐๐จ๐ฐ ๐ญ๐จ ๐๐ง๐ ๐ข๐ง๐๐๐ซ ๐ ๐๐๐ญ๐ญ๐๐ซ ๐๐จ๐ซ๐ฅ๐ will be out on March 26! W. W. Norton & Company




๐ฌ๐งWhat does the U.K. national anthem have to do with fire safety? ๐ฅ Iโm delighted to debut as a host for the Queen Elizabeth Prize for Engineering podcast Create the Future. In my first episode, I have a red-hot conversation w/ Luke Bisby & Jose Torero Royal Academy of Engineering Peanut & Crumb podcasts.apple.com/us/podcast/creโฆ


๐Very grateful for the feature review of "Wicked Problems" in nature : โMadhavan champions the importance of looking at seemingly technical problems through a wider lens...'Wicked Problems'ย is a wake-up call for all engineers to expand their mindset.โ nature.com/articles/d4158โฆ


๐พ What happens after you flush? I get my hands dirty for the next episode of the Queen Elizabeth Prize for Engineering #podcast โCreate the Future.โ Exploring the #engineering origins of public health, why sanitation is the "Other AI" & why the mundane is magnificent for maintenance. podcasts.apple.com/gb/podcast/theโฆ


Hot off the press from Kate Lurain Ramya Ramaswami TAO Elad Sharon Denise Whitby Important new data showing high and durable activity for anti-PD1 in HIV-KS! CITN12: Pembro in HIV-Associated Kaposi Sarcoma | JCO ascopubs.org/doi/10.1200/JCโฆ



Ramya Ramaswami National Cancer Institute et al (A11505) tested abemaciclib, a CDK4/6 inhibitor, in advanced KS, and found that a majority of patients (84%) had significant reduction in the size & extent of their KS

Phase I/II trial evaluates the safety and efficacy of abemaciclib in patients with HIV-associated and HIV-negative Kaposi sarcoma. Dr Ramya Ramaswami (Ramya Ramaswami) highlights the importance of the findings in the full interview ecancer.org/en/video/12382โฆ #ASCO25